MOBI — Mobia Medical, Inc. Common Stock stock price, charts and financials

QT30Mobia Medical, Inc. Common Stock

Mobia Medical, Inc. Common Stock (NASDAQ: MOBI) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
10.54
-0.32-2.95%
MOBIQT30Mobia Medical, Inc. Common Stock·NASDAQ
10.54-2.95%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand33.25MPerf Week5.29%
Market Cap350.44MForward P/E-EPS next Y-2.20Insider Trans-Shs Float2.06MPerf Month-7.71%
Enterprise Value181.78MPEG-EPS next Q-Inst Own-Short Float1.08%Perf Quarter-26.04%
Income-67.57MP/S13.70EPS this Y-Inst Trans-Short Ratio2.29Perf Half Y-
Sales25.58MP/B1.17EPS next Y25.27%ROA-19.86%Short Interest358.03KPerf YTD-24.71%
Book/sh-P/C-EPS next 5Y-ROE-1595.68%52W High15.29 -31.07%Perf Year-
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-19.24%52W Low9.85 7.01%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin82.80%Volatility7.51% 7.76%Perf 5Y-
Dividend TTM-EV/Sales7.11EPS Y/Y TTM-Oper. Margin-136.30%ATR (14)0.86Perf 10Y-
Dividend Ex-Date-Quick Ratio12.80Sales Y/Y TTM-Profit Margin-151.62%RSI (14)44.26Recom2.00
Dividend Gr. 3/5Y-Current Ratio13.28EPS Q/Q-107.55%SMA20-3.68%Beta-0.39Target Price25.00
Payout0.00%Debt/Eq0.05Sales Q/Q-SMA50-7.17%Rel Volume10.93Prev Close10.86
Employees167LT Debt/Eq-0.05EarningsAug 11SMA200-12.89%Avg Volume157.43KPrice10.54
IPO DateMay 08, 2026Option/ShortNo / YesEPS/Sales Surpr.-57.39% 10.95%Net Debt/EBITDA4.80Volume1,720,953Change-2.95%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26InitiatedBTIGBuy$19
Jun-02-26ReiteratedGoldman Sachs$31
Latest News· Times ET
Aug-28-26
Aug-12-26
Aug-11-26
Aug-03-26
Jul-21-26
Jul-15-26
Jul-14-26
Jul-02-26
Company

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
Total Revenue32
Cost of Goods Sold Incl. D&A6
Gross Profit26
Selling, General and Administrative Excl. Other66
Research and Development7
Other Operating Expense-1
Operating Income-46
Interest Expense1
Unusual Expense
Non-Operating Income (Expense)1
Net Income Before Taxes-46
Income Taxes
0
Consolidated Net Income-46
Net Income From Continuing Operations-46
Net Income-46
EPS (Recurring)-0.02
EPS (Basic, Before Extraordinaries)-0.02
EPS (Diluted)-0.02
EBITDA-45
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio
Gross Margin81.25
Operating Margin-143.75
Net Margin-143.75
Shares Outstanding23
Market Capitalization
Operating Lease Expense
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.